Helex

Helex is a biotechnology company based in New York, New York. The company employs 22 people and generates over $10,000 in annual revenue. Helex specializes in developing an epigenetic directed gene editing platform designed to enhance safety. Their focus is on addressing high-burden diseases currently lacking effective treatments. Helex distinguishes itself through its commitment to developing safer gene editing solutions. Their epigenetic directed approach aims to minimize unintended consequences associated with traditional gene editing techniques. For more information, visit their website at helex.bio.